Pike J, Mutebi A, Shah N, Jackson J, Cotton S, Desai PR, Sapra S. Factors associated with a history of failure and switching migraine prophylaxis treatment: an analysis of clinical practice data from the United States, Germany, France, and Japan. Value Health. 2016;19(3):A68.
Data on file. July 2019.
Zhang Q, Ruff D, Pearlman E, Govindan S, Aurora K. Efficacy of Galcanezumab in Patients Who Failed to Respond to Preventives Previously: Results from EVOLVE-1, EVOLVE-2 and REGAIN Studies. Neurology. 2018;90(Suppl 15):S20.004.
Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:3.
Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, Stokes M, Lipton RB. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56(2):306-322.
Shah AM, Bendtsen L, Zeeberg P, Jensen RH. Reduction of medication costs after detoxification for medication-overuse headache. Headache. 2013;53(4):665-672.
Bonafede M, Cappell K, Sapra S, Shah N, Desai P, Tepper S. Direct costs associated with migraine in the US. Neurology. 2017;88(Suppl 16):P1.180.
Ford J, Nyhuis A, Aurora S, Foster SA, Schroeder K. Cycling through migraine preventive treatments: implications to all-cause total direct costs. Cephalalgia. 2017;37(Suppl 1):272- 273.
Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96-107.
Subscribe to our Free Newsletters!